🚀 VC round data is live in beta, check it out!
Zhejiang Shouxiangu Valuation Multiples
Discover revenue and EBITDA valuation multiples for Zhejiang Shouxiangu and similar public comparables like Blau Farmacêutica, enGene, 4D Molecular Therapeutics, Genfit and more.
Zhejiang Shouxiangu Overview
About Zhejiang Shouxiangu
Zhejiang Shouxiangu Pharmaceutical Co Ltd is a Chinese pharmaceutical company.
Founded
2007
HQ
Employees
N/A
Website
Financials (FY)
EV
$464M
Zhejiang Shouxiangu Financials
Zhejiang Shouxiangu reported last fiscal year revenue of $101M and EBITDA of $39M.
In the same fiscal year, Zhejiang Shouxiangu generated $82M in gross profit, $39M in EBITDA, and $26M in net income.
Revenue (LTM)
Zhejiang Shouxiangu P&L
In the most recent fiscal year, Zhejiang Shouxiangu reported revenue of $101M and EBITDA of $39M.
Zhejiang Shouxiangu expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | — | XXX | $101M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $82M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 81% | XXX | XXX | XXX |
| EBITDA | — | XXX | $39M | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 39% | XXX | XXX | XXX |
| EBIT Margin | — | XXX | 20% | XXX | XXX | XXX |
| Net Profit | — | XXX | $26M | XXX | XXX | XXX |
| Net Margin | — | XXX | 25% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Zhejiang Shouxiangu Stock Performance
Zhejiang Shouxiangu has current market cap of $539M, and enterprise value of $464M.
Market Cap Evolution
Zhejiang Shouxiangu's stock price is $2.72.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $464M | $539M | 0.0% | XXX | XXX | XXX | $0.13 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialZhejiang Shouxiangu Valuation Multiples
Zhejiang Shouxiangu trades at 4.6x EV/Revenue multiple, and 11.8x EV/EBITDA.
EV / Revenue (LTM)
Zhejiang Shouxiangu Financial Valuation Multiples
As of April 20, 2026, Zhejiang Shouxiangu has market cap of $539M and EV of $464M.
Equity research analysts estimate Zhejiang Shouxiangu's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Zhejiang Shouxiangu has a P/E ratio of 21.0x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $539M | XXX | $539M | XXX | XXX | XXX |
| EV (current) | $464M | XXX | $464M | XXX | XXX | XXX |
| EV/Revenue | — | XXX | 4.6x | XXX | XXX | XXX |
| EV/EBITDA | — | XXX | 11.8x | XXX | XXX | XXX |
| EV/EBIT | — | XXX | 22.6x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 5.7x | XXX | XXX | XXX |
| P/E | — | XXX | 21.0x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (10.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Zhejiang Shouxiangu Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Zhejiang Shouxiangu Margins & Growth Rates
Zhejiang Shouxiangu's revenue in the last fiscal year declined by (12%).
Zhejiang Shouxiangu Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | — | XXX | (12%) | XXX | XXX | XXX |
| EBITDA Margin | — | XXX | 39% | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (25%) | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 33% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 5% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 7% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 60% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Zhejiang Shouxiangu Public Comps
See public comps and valuation multiples for other Biopharmaceuticals and Nutraceuticals & Cosmeceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Zhejiang Shouxiangu | XXX | XXX | XXX | XXX | XXX | XXX |
| Blau Farmacêutica | XXX | XXX | XXX | XXX | XXX | XXX |
| enGene | XXX | XXX | XXX | XXX | XXX | XXX |
| 4D Molecular Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Genfit | XXX | XXX | XXX | XXX | XXX | XXX |
| Entrada Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Zhejiang Shouxiangu M&A Activity
Zhejiang Shouxiangu acquired XXX companies to date.
Last acquisition by Zhejiang Shouxiangu was on XXXXXXXX, XXXXX. Zhejiang Shouxiangu acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Zhejiang Shouxiangu
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialZhejiang Shouxiangu Investment Activity
Zhejiang Shouxiangu invested in XXX companies to date.
Zhejiang Shouxiangu made its latest investment on XXXXXXXX, XXXXX. Zhejiang Shouxiangu invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Zhejiang Shouxiangu
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Zhejiang Shouxiangu
| When was Zhejiang Shouxiangu founded? | Zhejiang Shouxiangu was founded in 2007. |
| Where is Zhejiang Shouxiangu headquartered? | Zhejiang Shouxiangu is headquartered in China. |
| Is Zhejiang Shouxiangu publicly listed? | Yes, Zhejiang Shouxiangu is a public company listed on Shanghai Stock Exchange. |
| What is the stock symbol of Zhejiang Shouxiangu? | Zhejiang Shouxiangu trades under 603896 ticker. |
| When did Zhejiang Shouxiangu go public? | Zhejiang Shouxiangu went public in 2017. |
| Who are competitors of Zhejiang Shouxiangu? | Zhejiang Shouxiangu main competitors are Blau Farmacêutica, enGene, 4D Molecular Therapeutics, Genfit. |
| What is the current market cap of Zhejiang Shouxiangu? | Zhejiang Shouxiangu's current market cap is $539M. |
| What is the current revenue of Zhejiang Shouxiangu? | Zhejiang Shouxiangu's last fiscal year revenue is $101M. |
| What is the current EV/Revenue multiple of Zhejiang Shouxiangu? | Current revenue multiple of Zhejiang Shouxiangu is 4.6x. |
| Is Zhejiang Shouxiangu profitable? | No, Zhejiang Shouxiangu is not profitable. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.